Chapter 1 Executive Summary
- Market Outlook
- Scope of Report
- Market Summary
- Market Value
Chapter 2 Market Overview
- Cell and Gene Therapy Overview
- Regulatory Landscape
- U.S. (FDA)
- Europe
Chapter 3 Market Dynamics
- Market Dynamics
- Market Drivers
- Market Restraints
- Market Opportunities
Chapter 4 Market Segmentation Analysis
- Segmentation Breakdown
- Global Market for Cell and Gene Therapy
- Market Size and Forecast
- Market Analysis
- Cell Therapy
- Gene-modified Cell Therapy
- Gene Therapy
- Global Market for Gene-modified Cell Therapy and Gene Therapy by Vector Type
- Market Size and Forecast
- Market Analysis
- Adeno-Associated Viral (AAV) Vectors
- Retroviral Vectors
- Lentiviral Vectors
- Others
- Global Market for Cell and Gene Therapy by Drug Product
- Market Size and Forecast
- Zolgensma
- Yescarta
- Kymriah
- Abecma
- Maci
- Tecartus
- Epicel
- Others
- Global Market for Cell and Gene Therapy by Application
- Market Size and Forecast
- Oncology
- Rare Diseases
- Ophthalmology
- Other Therapeutic Areas
- Geographic Breakdown
- Global Market for Cell and Gene Therapy by Region
- Market Size and Forecast
- North America
- Market Size and Forecast
- U.S.
- Canada
- Mexico
- Europe
- Market Size and Forecast
- Germany
- U.K.
- France
- Rest of Europe
- Asia-Pacific
- Market Size and Forecast
- Japan
- Cina
- Australia
- Rest of Asia-Pacific
- Rest of the World
- Market Size and Forecast
Chapter 5 Competitive Intelligence
- Investment Outlook
- Mergers and Acquisitions
- Competitive Landscape: Overview
- Market Share Analysis
- Strategic Acquisitions and Collaborations
- Pipeline Analysis
Chapter 6 Sustainability: An ESG Perspective
List of Tables
Summary Table: Global Market for Cell and Gene Therapy, by Type of Therapy, Through 2028
Table 1: Approved Cell Therapy Products (Including Withdrawn Products), 2023
Table 2: Approved Gene Therapy Products (Including Withdrawn Products), 2023
Table 3: Total Number of New Cases and Deaths Due to Various Cancers Globally, 2020
Table 4: Comparison of Accelerated Approvals for Various Drugs
Table 5: Global Market for Cell and Gene Therapy, by Type of Therapy, Through 2028
Table 6: Global Market for Cell Therapy, by Region, Through 2028
Table 7: Approved CAR-T Products, as of December 2023
Table 8: Global Market for Gene-modified Cell Therapy, by Region, Through 2028
Table 9: Global Market for Gene Therapy, by Region, Through 2028
Table 10: Global Market for Gene-modified Cell Therapy and Gene Therapy, by Vector Type, Through 2028
Table 11: Global Market for Cell and Gene Therapy, by Drug Product, Through 2028
Table 12: Global Market for Cell and Gene Therapy, by Application, Through 2028
Table 13: Global Market for Cell and Gene Therapy for Oncology, by Region, Through 2028
Table 14: Global Market for Cell and Gene Therapy for Rare Diseases, by Region, Through 2028
Table 15: Global Market for Cell and Gene Therapy for Ophthalmology, by Region, Through 2028
Table 16: Global Market for Cell and Gene Therapy for Other Therapeutic Areas, by Region, Through 2028
Table 17: Global Market for Cell and Gene Therapy, by Region, Through 2028
Table 18: North American Market for Cell and Gene Therapy, by Country, Through 2028
Table 19: European Market for Cell and Gene Therapy, by Country, Through 2028
Table 20: Asia-Pacific Market for Cell and Gene Therapy, by Country, Through 2028
Table 21: Strategic Acquisitions and Collaborations Portfolio, 2021-2023
Table 22: Total Number of Clinical Trials, by Indication, 2023 (Q3)
Table 23: Key Cell and Gene Therapy Drug Candidates in Phase I Trials
Table 24: Key Cell and Gene Therapy Drug Candidates in Phase II Trials
Table 25: Key Cell and Gene Therapy Drug Candidates in Phase III Trials
Table 26: Key Cell and Gene Therapy Drug Candidates in Supplemental Indication and Formulation Expansions
Table 27: Cell and Gene Therapy Drug Awaiting Approvals
Table 28: Environmental Initiatives, by Various Cell and Gene Therapy Companies
Table 29: ESG Rankings for Companies in the Cell and Gene Therapy Market, 2023
Table 30: Amgen Inc.: Company Snapshot
Table 31: Amgen Inc.: Financial Performance, FY 2021 and 2022
Table 32: Amgen Inc.: Product Portfolio
Table 33: Amgen Inc: News/Key Developments, 2021
Table 34: Bluebird Bio Inc.: Company Snapshot
Table 35: Bluebird Bio Inc.: Financial Performance, FY 2021 and 2022
Table 36: Bluebird Bio Inc.: Product Portfolio
Table 37: Bluebird Bio Inc.: News/Key Developments,2022 and 2023
Table 38: Bristol Myers Squibb Co.: Company Snapshot
Table 39: Bristol-Myers Squibb Co.: Financial Performance, FY 2021 and 2022
Table 40: Bristol-Myers Squibb Co.: Product Portfolio
Table 41: Bristol-Myers Squibb Co: News/Key Developments, 2022 and 2023
Table 42: Dendreon Pharmaceuticals LLC: Company Snapshot
Table 43: Dendreon Pharmaceuticals LLC: Product Portfolio
Table 44: Dendreon Pharmaceuticals LLC: News/Key Developments, 2021
Table 45: Ferring Pharmaceuticals: Company Snapshot
Table 46: Ferring Pharmaceuticals: Financial Performance, FY 2021 and 2022
Table 47: Ferring Pharmaceuticals: Product Portfolio
Table 48: Ferring Pharmaceuticals: News/Key Developments, 2022 and 2023
Table 49: Gilead Sciences Inc.: Company Snapshot
Table 50: Gilead Sciences Inc.: Financial Performance, FY 2021 and 2022
Table 51: Gilead Sciences Inc.: Product Portfolio
Table 52: Gilead Sciences Inc.: News/Key Developments, 2021-2023
Table 53: Iovance Biotherapeutics Inc.: Company Snapshot
Table 54: Johnson & Johnson Services Inc.: Company Snapshot
Table 55: Johnson & Johnson Services Inc.: Financial Performance, FY 2021 and 2022
Table 56: Johnson & Johnson Services Inc: Product Portfolio
Table 57: Johnson & Johnson Services Inc: News/Key Developments, 2023
Table 58: Krystal Biotech Inc.: Company Snapshot
Table 59: Krystal Biotech Inc.: Product Portfolio
Table 60: Mallinckrodt PLC: Company Snapshot
Table 61: Mallinckrodt PLC: Financial Performance, FY 2021 and 2022
Table 62: Mallinckrodt PLC: Product Portfolio
Table 63: Mallinckrodt PLC: News/Key Developments, 2022 and 2023
Table 64: Novartis AG: Company Snapshot
Table 65: Novartis AG: Financial Performance, FY 2021 and 2022
Table 66: Novartis AG: Product Portfolio
Table 67: Novartis AG: News/Key Developments, 2021-2023
Table 68: Orchard Therapeutics Plc.: Company Snapshot
Table 69: Orchard Therapeutics Plc.: Financial Performance, FY 2021 and 2022
Table 70: Orchard Therapeutic PLC: Product Portfolio
Table 71: Orchard Therapeutic PLC: News/Key Developments, 2021-2023
Table 72: Pharmicell Co. Ltd.: Company Snapshot
Table 73: Pharmicell Co. Ltd.: Product Portfolio
Table 74: Uniqure N.V.: Company Snapshot
Table 75: Uniqure N.V.: Product Portfolio
Table 76: Uniqure N.V.: News/Key Developments, 2023
Table 77: Vericel Corp.: Company Snapshot
Table 78: Vericel Corp.: Financial Performance, FY 2021 and 2022
Table 79: Vericel Corp.: Product Portfolio
Table 80: Vericel Corp.: News/Key Developments, 2022
Table 81: Abbreviations
List of Figures
Summary Figure: Global Market for Cell and Gene Therapy, by Type of Therapy, 2020-2028
Figure 1: Various Gene Therapy Strategies
Figure 2: Administration Routes in Gene Therapy
Figure 3: Cell Therapy Products - Regulatory Pathway
Figure 4: Cell and Gene Therapy Market Dynamics
Figure 5: Global Market for Cell and Gene Therapy, by Type of Therapy, 2020-2028
Figure 6: Global Market Shares of Cell and Gene Therapy, by Type of Therapy, 2022
Figure 7: Global Market for Cell Therapy, by Region, 2020-2028
Figure 8: Global Market for Gene-modified Cell Therapy, by Region, 2020-2028
Figure 9: Global Market for Gene Therapy, by Region, 2020-2028
Figure 10: Global Market for Gene-modified Cell Therapy and Gene Therapy, by Vector Type, 2020-2028
Figure 11: Global Market Shares of Gene-modified Cell Therapy and Gene Therapy, by Vector Type, 2022
Figure 12: Global Market for AAV Vectors for Gene-modified Cell Therapy and Gene Therapy, 2020-2028
Figure 13: Global Market for Retroviral Vectors for Gene-modified Cell Therapy and Gene Therapy, 2020-2028
Figure 14: Global Market for Lentiviral Vectors for Gene-modified Cell Therapy and Gene Therapy, 2020-2028
Figure 15: Global Market for Other Vectors Used in Gene-modified Cell Therapy and Gene Therapy, 2020-2028
Figure 16: Global Market for Cell and Gene Therapy, by Drug Product, 2020-2028
Figure 17: Global Market Shares of Cell and Gene Therapy, by Drug Product, 2022
Figure 18: Global Market for Zolgensma Drug for Cell and Gene Therapy, 2020-2028
Figure 19: Global Market for Yescarta Drug for Cell and Gene Therapy, 2020-2028
Figure 20: Global Market for Kymriah Drug for Cell and Gene Therapy, 2020-2028
Figure 21: Global Market for Abecma Drug for Cell and Gene Therapy, 2020-2028
Figure 22: Global Market for Maci Drug for Cell and Gene Therapy, 2020-2028
Figure 23: Global Market for Tecartus Drug for Cell and Gene Therapy, 2020-2028
Figure 24: Global Market for Epicel Drug for Cell and Gene Therapy, 2020-2028
Figure 25: Global Market for Other Types of Drugs Used for Cell and Gene Therapy, 2020-2028
Figure 26: Global Market for Cell and Gene Therapy, by Application, 2020-2028
Figure 27: Global Market Shares of Cell and Gene Therapy, by Application, 2022
Figure 28: Global Market for Cell and Gene Therapy for Oncology, by Region, 2020-2028
Figure 29: Global Market for Cell and Gene Therapy for Rare Diseases, by Region, 2020-2028
Figure 30: Global Market for Cell and Gene Therapy for Ophthalmology, by Region, 2020-2028
Figure 31: Global Market for Cell and Gene Therapy for Other Therapeutic Areas, by Region, 2020-2028
Figure 32: Global Market for Cell and Gene Therapy, by Region, 2020-2028
Figure 33: Global Market Shares of Cell and Gene Therapy, by Region, 2022
Figure 34: North American Market Shares of Cell and Gene Therapy, by Country, 2022
Figure 35: U.S. Market for Cell and Gene Therapy, 2020-2028
Figure 36: Canadian Market for Cell and Gene Therapy, 2020-2028
Figure 37: Mexican Market for Cell and Gene Therapy, 2020-2028
Figure 38: European Market Shares of Cell and Gene Therapy, by Country, 2022
Figure 39: German Market for Cell and Gene Therapy, 2020-2028
Figure 40: U.K. Market for Cell and Gene Therapy, 2020-2028
Figure 41: French Market for Cell and Gene Therapy, 2020-2028
Figure 42: Rest of European Market for Cell and Gene Therapy, 2020-2028
Figure 43: Asia-Pacific Market Shares of Cell and Gene Therapy, by Country, 2022
Figure 44: Japanese Market for Cell and Gene Therapy, 2020-2028
Figure 45: Chinese Market for Cell and Gene Therapy, 2020-2028
Figure 46: Australian Market for Cell and Gene Therapy, 2020-2028
Figure 47: Rest of Asia-Pacific Market for Cell and Gene Therapy, 2020-2028
Figure 48: Rest of the World Market for Cell and Gene Therapy, 2020-2028
Figure 49: Investments, by Year, 2017-2022
Figure 50: Equity Offering and Venture Financing, 2021 and 2022
Figure 51: Public and Private Companies Deal Value, 2021 and 2022
Figure 52: Number of Deals, 2021 and 2022
Figure 53: M&A Deals, 2021 and 2022
Figure 54: Strategic Alliance Deals, 2021 and 2022
Figure 55: Global Market Shares of Cell and Gene Therapy Drugs, by Company, 2022
Figure 56: Total Number of Clinical Trials, by Phase, 2023 (Q3)
Figure 57: Number of Cell and Gene Therapy Developers, by Region, 2023 (Q3)
Figure 58: ESG in Cell and Gene Therapy Industry
Figure 59: Amgen Inc.: Revenue Shares, by Business Unit, FY 2022
Figure 60: Amgen Inc.: Revenue Shares, by Country/Region, FY 2022
Figure 61: Bluebird Bio Inc.: Revenue Shares, by Business Unit, FY 2022
Figure 62: Bristol-Myers Squibb Co.: Revenue Shares, by Business Unit, FY 2022
Figure 63: Bristol-Myers Squibb Co.: Revenue Shares, by Country/Region, FY 2022
Figure 64: Ferring Pharmaceuticals: Revenue Shares, by Business Unit, FY 2022
Figure 65: Ferring Pharmaceuticals: Revenue Shares, by Country/Region, FY 2022
Figure 66: Gilead Sciences Inc.: Revenue Shares, by Business Unit, FY 2022
Figure 67: Gilead Sciences Inc.: Revenue Shares, by Country/Region, FY 2022
Figure 68: Johnson & Johnson Services Inc.: Revenue Shares, by Business Unit, FY 2022
Figure 69: Johnson & Johnson Services Inc.: Revenue Shares, by Country/Region, FY 2022
Figure 70: Mallinckrodt PLC: Revenue Shares, by Business Unit, FY 2022
Figure 71: Mallinckrodt PLC: Revenue Shares, by Country/Region, FY 2022
Figure 72: Novartis AG: Revenue Shares, by Business Unit, FY 2022
Figure 73: Novartis AG: Revenue Shares, by Country/Region, FY 2022
Figure 74: Orchard Therapeutic PLC: Revenue Shares, by Business Unit, FY 2022
Figure 75: Orchard Therapeutic PLC: Revenue Shares, by Country/Region, FY 2022
Figure 76: Vericel Corp.: Revenue Shares, by Business Unit, FY 2022
